Anvifen 250 mg 20 pcs. capsules Pharmproekt JSC/Ropharma JSC

Nosological classification (ICD-10)

• F06.6 Organic emotionally labile [asthenic] disorder
• F10.3 Withdrawal state
• F41.9 Anxiety disorder, unspecified
• F48.9 Neurotic disorder, unspecified
• F95.9 Tics, unspecified
• F98.0 Enuresis of inorganic nature
• F98.5 Stuttering [stammering]
• G47 Sleep disorders
• H81.0 Meniere's disease
• H81.4 Dizziness of central origin
• H81.9 Vestibular function disorder, unspecified
• T75.3 Motion sickness

What does it help with?

Indications for use are a decrease in the efficiency of brain function and psycho-emotional disorders, as the main remedy for non-severe conditions and in complex therapy in case of severe conditions of patients.

What is it prescribed for? The use of Anvifen brings a significant effect when:

• Anxious, restless states, tension and depression;
• For neuroses;
• Headaches and dizziness;
• Insomnia;
• Disorders of the vestibular apparatus;
• Alcohol withdrawal and asthenic syndromes;
• Meniere's disease;
• Recovery from traumatic brain injury;
• With bruxism;
• Children's nervous disorders: tics, enuresis, stuttering, neuritis;
• For hyperactivity.

During the treatment process, there is an increase in motivation and interest in the patient.

As a nootropic drug, Anvifen is used for:

• normalization and improvement of memory, attention, concentration, accuracy of movements;
• improving cognitive functions;
• stabilization of emotional activity;
• improving learning processes;
• activation of intellectual activity;
• increasing endurance and exercise tolerance;
• reducing signs of irritability and aggression.

Anvifen is often used for mental retardation and ADHD, for convulsive syndrome and epilepsy to improve brain metabolism and increase the tone of the cortex.

Compound

What it is?

What is it for? Anvifen is a drug that increases the efficiency of brain processes and also has a sedative and psychostimulating effect. In what cases is it used? What does this medicine help with?

Anfiven is a nootropic used to optimize mental and physical performance. In addition, it relieves feelings of anxiety and tension, and normalizes sleep.

The main active ingredient included in the drug is aminophenylbutyric acid. In addition, the medicine contains auxiliary components that help to quickly assimilate the main components:

• lactose;
• hyprolose;
• silicon dioxide and titanium;
• Magnesium stearate.

Description of the dosage form

Capsules, 25 mg: hard gelatin, size No. 3, white.

Capsules, 50 mg: hard gelatin, size No. 3, white body, blue cap.

Capsules, 125 mg: hard gelatin, size No. 2, white body, blue cap.

Capsules, 250 mg: hard gelatin, size No. 0, white body, dark blue cap.

Capsule contents: a mixture of powder and/or granules of white or white with a yellowish tint.

Reviews

Reviews about the drug are mostly positive. Patients who have taken the drug note the effectiveness of action, ease of administration and dosage.

Reviews from adults after use:

• “Anvifen helped cope with panic attacks, it’s an effective remedy.”
• “Improves overall emotional state, helps cope with depression.”
• "Does not irritate the gastric mucosa."
• “Anvifen is effective for phobias and seizures.”
• “Anvifen helped a lot with motion sickness.”
• “I took Anvifen for insomnia, it helped quickly.”
• “Easy to take, capsules of different dosages, no need to crush the tablet to get the prescribed dose.”
• “I take Anvifen to improve memory and attention, I like that I can continue to work as usual during the course, it does not reduce my concentration.”

Reviews from neurologists:

• “I use Anvifen when prescribing treatment for patients, it copes well with panic attacks and depression.”
• “It’s a good drug, I haven’t noticed any side effects during my practice.”
• “Anvifen is an excellent remedy for recovery from traumatic brain injuries.”
• “Anvifen is convenient in a wide range of dosages, affordable, effective, side effects and addiction are rare.”

Pharmacodynamics

A nootropic agent that facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct effect on GABAergic receptors). The tranquilizing effect is combined with an activating effect. It also has antiplatelet, antioxidant and some anticonvulsant effects.

Improves the functional state of the brain by normalizing its metabolism and influencing cerebral blood flow (increases volumetric and linear velocity, reduces vascular resistance, improves microcirculation, and has an antiplatelet effect). Extends the latent period and shortens the duration and severity of nystagmus.

Does not affect cholinergic and adrenergic receptors. Reduces vasovegetative symptoms (including headache, feeling of heaviness in the head, sleep disturbance, irritability, emotional lability). When taken as a course, it increases physical and mental performance (attention, memory, speed and accuracy of sensory-motor reactions).

Reduces manifestations of asthenia (improves well-being, increases interest and initiative - motivation for activity) without sedation or agitation.

Helps reduce feelings of anxiety, tension and restlessness, and normalizes sleep.

In elderly people, it does not cause depression of the central nervous system; the muscle-relaxing aftereffect is most often absent.

Anvifen 250 mg 20 pcs. capsules Pharmproekt JSC/Ropharma JSC

pharmachologic effect

A nootropic drug that facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct effect on GABAergic receptors).
The tranquilizing effect is combined with an activating effect. It also has antiplatelet, antioxidant and some anticonvulsant effects. Improves the functional state of the brain by normalizing its metabolism and influencing cerebral blood flow (increases volumetric and linear velocity, reduces vascular resistance, improves microcirculation, and has an antiplatelet effect). Extends the latent period and shortens the duration and severity of nystagmus.

Does not affect cholinergic and adrenergic receptors. Reduces vasovegetative symptoms (including headache, feeling of heaviness in the head, sleep disturbances, irritability, emotional lability). When taken as a course, it increases physical and mental performance (attention, memory, speed and accuracy of sensory-motor reactions).

Reduces manifestations of asthenia (improves well-being, increases interest and initiative (motivation of activity)) without sedation or agitation. Helps reduce feelings of anxiety, tension and restlessness, and normalizes sleep.

In elderly people, it does not cause depression of the central nervous system; the muscle-relaxing aftereffect is most often absent.

Composition and release form Anvifen 250 mg 20 pcs. capsules Pharmproekt JSC/Ropharma JSC

Capsules - 1 capsule:

• Active substance: aminophenylbutyric acid hydrochloride 250 mg
• Excipients: hyprolose - 2.0 mg, colloidal silicon dioxide - 8.0 mg, lactose - 86.5 mg, magnesium stearate - 3.5 mg.
• Composition of the capsule shell: gelatin, azorubine dye (E122), brilliant blue dye (E133), titanium dioxide (E171), water.

10 pieces. — contour cellular packaging (2) — cardboard packs.

Description of the dosage form

Hard gelatin capsules, No. 0, white body, dark blue cap; the contents of the capsules are a mixture of powder and/or granules that are white or white with a yellowish tint.

Directions for use and doses

Orally after meals in 2-3 week courses.

Adults and children over 14 years of age: 250-500 mg 3 times a day (maximum daily dose 2500 mg). Children from 3 to 8 years old: 50-100 mg 3 times a day; from 8 to 14 years - 250 mg 3 times a day.

The single maximum dose in adults and children over 14 years of age is 750 mg, in patients over 60 years of age - 500 mg, in children under 8 years of age - 150 mg, from 8 to 14 years of age - 250 mg.

For alcohol withdrawal syndrome - 250-500 mg 3 times a day and at night - 750 mg, with a gradual decrease in the daily dose to the usual for adults.

For the treatment of dizziness due to dysfunction of the vestibular apparatus and Meniere's disease - 250 mg 3 times a day for 14 days.

To prevent motion sickness - 250-500 mg once 1 hour before the expected start of motion sickness or when the first symptoms of seasickness appear. The anti-motion sickness effect of Anvifen® increases with increasing dose of the drug. When severe manifestations of seasickness occur (vomiting, etc.), the use of Anvifen® is ineffective even in doses of 750-1000 mg.

Pharmacodynamics

A nootropic agent that facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct effect on GABAergic receptors). The tranquilizing effect is combined with an activating effect. It also has antiaggregation, antioxidant and some anticonvulsant effects. Improves the functional state of the brain by normalizing its metabolism and influencing cerebral blood flow (increases volumetric and linear velocity, reduces vascular resistance, improves microcirculation, and has an antiaggregation effect). Extends the latent period and shortens the duration and severity of nystagmus. Does not affect cholinergic and adrenergic receptors. Reduces vasovegetative symptoms (including headache, feeling of heaviness in the head, sleep disturbances, irritability, emotional lability). When taken as a course, it increases physical and mental performance (attention, memory, speed and accuracy of sensory-motor reactions). Reduces manifestations of asthenia (improves well-being, increases interest and initiative (motivation of activity) without sedation or agitation. Helps reduce feelings of anxiety, tension and restlessness, normalizes sleep. In elderly people it does not cause depression of the central nervous system, muscle-relaxing aftereffects are most often absent.

Pharmacokinetics

Suction and distribution

Absorption is high, penetrates well into all tissues of the body and through the BBB (about 0.1% of the administered dose of the drug penetrates into brain tissue, and in young and elderly people to a much greater extent). Evenly distributed in the liver and kidneys.

Metabolism and excretion

Metabolized in the liver - 80-95%, metabolites are not pharmacologically active. Does not accumulate. After 3 hours, it begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and is detected within another 6 hours. About 5% is excreted by the kidneys unchanged, partly with bile.

Indications for use Anvifen 250 mg 20 pcs. capsules Pharmproekt JSC/Ropharma JSC

• asthenic and anxiety-neurotic conditions;
• stuttering, tics and enuresis in children;
• insomnia and night anxiety in elderly patients;
• Meniere's disease, dizziness associated with dysfunctions of the vestibular analyzer of various origins;
• prevention of motion sickness during kinetosis;
• as part of complex therapy of alcohol withdrawal syndrome for the relief of psychopathological and somatovegetative disorders.

Contraindications

• hypersensitivity to the components of the drug;
• pregnancy;
• breast-feeding;
• children under 3 years of age.

The drug should be used with caution in case of erosive and ulcerative lesions of the gastrointestinal tract and liver failure.

Application of Anvifen 250 mg 20 pcs. Pharmproekt AO/Ropharma AO capsules during pregnancy and breastfeeding

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Use in children

Contraindicated for use in children under 3 years of age.

special instructions

With long-term use, it is necessary to periodically monitor liver and peripheral blood function indicators.

Impact on the ability to drive vehicles and operate machinery

It is necessary to refrain from potentially dangerous activities that require increased concentration.

Overdose

Symptoms: severe drowsiness, nausea, vomiting, fatty liver (ingestion of more than 7 g), eosinophilia, decreased blood pressure, impaired renal function.

Treatment: gastric lavage, taking activated charcoal and carrying out symptomatic therapy.

Side effects Anvifen 250 mg 20 pcs. capsules Pharmproekt JSC/Ropharma JSC

Possible: drowsiness, nausea, increased irritability, agitation, anxiety, dizziness, headache (at first doses), allergic reactions.

Drug interactions

Extends and enhances the effect of sleeping pills, narcotic analgesics, neuroleptics, antiparkinsonian and antiepileptic drugs.

Pharmacokinetics

Absorption is high, penetrates well into all tissues of the body and through the BBB (about 0.1% of the administered dose of the drug penetrates into brain tissue, and in young and elderly people to a much greater extent). Evenly distributed in the liver and kidneys. Metabolized in the liver - 80–95%, metabolites are pharmacologically inactive. Does not accumulate. After 3 hours, it begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and is detected for another 6 hours. About 5% is excreted by the kidneys unchanged, partially with bile.

Side effects

In the initial stages, the patient may have a headache, dizziness or nausea. After 3 days from the moment you start taking Anvifen, these symptoms disappear.

In cases of non-compliance with the drug regimen or individual intolerance, side effects may occur, such as:

• Allergy;
• Desire to sleep;
• Irritability.

If symptoms worsen, you should consult a doctor.

In case of an overdose, the following side effects are possible: severe nausea, vomiting, drowsiness, low blood pressure, and kidney problems. It is necessary to rinse the stomach and take activated charcoal.

Contraindications to taking Anvifen are:

• Age up to 3 years;
• Pregnancy and breastfeeding period;
• Intolerance to substances included in the composition.

The risk of withdrawal syndrome upon completion of the course is minimal.

The instructions recommend not to drive during the course of treatment.

Directions for use and doses

Orally, after meals, in 2-3 week courses.

Adults and children over 14 years of age - 250-500 mg 3 times a day (maximum daily dose - 2500 mg). Children 3–8 years old - 50–100 mg 3 times a day; 8 - 14 years - 250 mg 3 times a day.

The single maximum dose for adults and children over 14 years of age is 750 mg, for persons over 60 years of age - 500 mg, for children under 8 years of age - 150 mg, from 8 to 14 years of age - 250 mg.

Alcohol withdrawal syndrome: 250–500 mg 3 times a day and 750 mg at night, with a gradual reduction in the daily dose to the usual for adults.

Treatment of dizziness with dysfunction of the vestibular apparatus and Meniere's disease: 250 mg 3 times a day for 14 days.

Prevention of motion sickness: 250–500 mg once, 1 hour before the expected start of motion sickness or when the first symptoms of seasickness appear.

The anti-motion sickness effect of Anvifen® increases with increasing dose of the drug. When severe manifestations of seasickness occur (vomiting, etc.), the use of Anvifen® is ineffective even in doses of 750–1000 mg.

Alcohol compatibility

It is not advisable to take Anvifen with acoloids. This includes compatibility with alcohol with low ethanol content. Such as, for example, beer, most varieties of which contain 3.5-5% pure ethyl. Ethanol negatively affects the treatment and effect of the product. It also negatively affects the liver, increasing the load on it, which can lead to undesirable consequences.

The drug is used for alcohol withdrawal syndrome, accelerating the elimination of alcohol from the body.